Drugs List

Dosage

Treatment
Morning and evening wash and dry the foot, smooth cream onto the affected area. Ensure the cream is massaged between the toes, then dust with powder. Clean socks or stockings dusted inside with undecenoates powder, should be worn every day.

Continue the treatment for one week after signs of infection have disappeared.

Prevention
Each day rub cream onto foot. Wear clean socks or stockings dusted with undecenoates powder every day.

Contraindications

None known

Precautions and Warnings

Repeat treatment occasionally to prevent re-infection
Avoid contact with eyes and mucous membranes
Do not apply to broken or denuded skin
Advise patient to discontinue use if severe or persistent irritation occurs

Pregnancy - See 'Pregnancy' section

Breastfeeding - See 'Lactation' section

Pregnancy and Lactation

Pregnancy

No data available however it is not considered to constitute a hazard.

The use of all medication in pregnancy should be avoided whenever possible; particularly in the first trimester. Non-drug treatments should also be considered. When essential, a medication with the best safety record over time should be chosen, employing the lowest effective dose for the shortest possible time. Polypharmacy should be avoided. Teratogens taken in the pre-embryonic period, often quoted as lasting until 14-17 days post-conception, are believed to have an all-or-nothing effect. Where drugs have a short half-life, and when the date of conception is certain, this may allow women to be reassured where drug exposure has occurred within this time frame. Further advice may be available from the UK National Teratology Information Service (NTIS) and through ToxBase, available via password on the internet ( www.toxbase.org ) or if this is unavailable at the backup site ( www.toxbasebackup.org ).

Lactation

No data available however it is not considered to constitute a hazard.

Neonates, infants born prematurely, those with low birth weight, those with an unstable gastrointestinal function or who have serious illnesses may require special consideration. For any infant, if a drug is prescribed to the nursing mother, it should be at the lowest practical dose and for the shortest time. When drug administration is unavoidable and breastfeeding is to continue, minimisation of exposure of the infant to the drug may sometimes be achieved by timing the maternal doses to just after a feeding episode. Infants exposed to drugs via breast milk should be monitored for unusual signs or symptoms. Interactions between the drug received by the infant from the mother's milk and medication prescribed for the infant should also be considered, for example, when the drug given to the infant may prevent metabolism of the drug received via breast milk.
Specialist advice is available from the UK Drugs in Lactation Advisory Service at https://www.midlandsmedicines.nhs.uk/content.asp?section=6&subsection=17&pageIdx=1

Presentation

Cream containing zinc undecenoate 20% w/w and undecenoic acid 5% w/w

Dusting powder containing zinc undecenoate 20% w/w and undecenoic acid 2% w/w

Drugs List

Dosage

Treatment
Morning and evening wash and dry the foot, smooth cream onto the affected area. Ensure the cream is massaged between the toes, then dust with powder. Clean socks or stockings dusted inside with undecenoates powder, should be worn every day.

Continue the treatment for one week after signs of infection have disappeared.

Prevention
Each day rub cream onto foot. Wear clean socks or stockings dusted with undecenoates powder every day.

Contraindications

None known

Precautions and Warnings

Repeat treatment occasionally to prevent re-infection
Avoid contact with eyes and mucous membranes
Do not apply to broken or denuded skin
Advise patient to discontinue use if severe or persistent irritation occurs

Pregnancy - See 'Pregnancy' section

Breastfeeding - See 'Lactation' section

Pregnancy and Lactation

Pregnancy

No data available however it is not considered to constitute a hazard.

The use of all medication in pregnancy should be avoided whenever possible; particularly in the first trimester. Non-drug treatments should also be considered. When essential, a medication with the best safety record over time should be chosen, employing the lowest effective dose for the shortest possible time. Polypharmacy should be avoided. Teratogens taken in the pre-embryonic period, often quoted as lasting until 14-17 days post-conception, are believed to have an all-or-nothing effect. Where drugs have a short half-life, and when the date of conception is certain, this may allow women to be reassured where drug exposure has occurred within this time frame. Further advice may be available from the UK National Teratology Information Service (NTIS) and through ToxBase, available via password on the internet ( www.toxbase.org ) or if this is unavailable at the backup site ( www.toxbasebackup.org ).

Lactation

No data available however it is not considered to constitute a hazard.

Neonates, infants born prematurely, those with low birth weight, those with an unstable gastrointestinal function or who have serious illnesses may require special consideration. For any infant, if a drug is prescribed to the nursing mother, it should be at the lowest practical dose and for the shortest time. When drug administration is unavoidable and breastfeeding is to continue, minimisation of exposure of the infant to the drug may sometimes be achieved by timing the maternal doses to just after a feeding episode. Infants exposed to drugs via breast milk should be monitored for unusual signs or symptoms. Interactions between the drug received by the infant from the mother's milk and medication prescribed for the infant should also be considered, for example, when the drug given to the infant may prevent metabolism of the drug received via breast milk.
Specialist advice is available from the UK Drugs in Lactation Advisory Service at https://www.midlandsmedicines.nhs.uk/content.asp?section=6&subsection=17&pageIdx=1

Overdosage

It is strongly recommended that the UK National Poisons Information Service be consulted on cases of suspected or actual overdose where there is doubt over the degree of risk or about appropriate management.

The following number will direct the caller to the relevant local centre (0844) 892 0111

Information may be obtained if you have access to ToxBase the primary clinical toxicology database of the National Poisons Information Service. This is available via password on the internet ( www.toxbase.org ) or if this is unavailable at the backup site ( www.toxbasebackup.org ).

Pharmacological Properties

Reference Sources

British National Formulary, 60th Edition (2010) Pharmaceutical Press, London.

Summary of Product Characteristics: Mycota cream. Thornton and Ross Ltd. Revised March 2009.
Summary of Product Characteristics: Mycota powder. Thornton and Ross Ltd. Revised November 2009.